Company Overview
DocGo Inc. operates as a mobile healthcare services company in the United States and the United Kingdom. It operates through Mobile Health Services and Transportation Services segments. The company offers transportation services comprising emergency response services; and non-emergency transport services, such as ambulance and wheelchair transportation services. It also provides mobile health services through its care delivery platform that are performed at home, offices, and other locations comprising mobile urgent care, exams, vaccinations, monitoring and care management, procedures, point-of-care tests, and screenings and coaching; event services, including on-site healthcare support at sporting events and concerts; virtual care management; and remote patient monitoring and chronic disease management services. The company serves municipalities, hospitals and health systems, states and communities, insurers, physician practices, health plans, and businesses and employees. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 27.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.26.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $322.20M (-47.7% YoY); net profit $-182.40M.
- Trailing 12 Months Year-on-year growth — revenue -21.3%, earnings -1012.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.91% |
| 1 Year: | -21.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -1,012.36% |
Stock Price Performance
| 1 Year: | -76.71% |
| 6 Months: | -40.03% |
| 3 Months: | -27.91% |
| 1 Month: | -35.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 76.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DCGO DocGo Inc. R2KPHARMA | 0.40 | -0.21 | $39.51M | 0.00% | -119.00% | -97.78% | 27.91% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.69M | 62.19M | 85.84M | 117.89M | 109.52M | 104.32M | 113.00M | 125.49M | 186.55M | 192.09M | 164.95M | 138.68M | 96.03M | 80.42M | 70.81M | 75.55M |
| Operating Income | -1.87M | 258.76K | 1.52M | 10.09M | 7.46M | 4.20M | -6.90M | 1.58M | 8.71M | 15.88M | 10.15M | 10.14M | -14.00M | -17.48M | -41.98M | -18.71M |
| Net Income | -2.00M | 102.01K | 801.57K | 10.63M | 11.76M | 2.47M | -3.47M | - | - | 11.23M | 6.53M | 5.50M | -9.41M | -11.16M | -27.77M | -14.76M |
| Diluted EPS | -0.03 | -18.19 | 0.04 | 0.09 | 0.11 | 0.03 | -0.03 | -0.02 | 0.05 | 0.10 | 0.06 | 0.05 | -0.09 | -0.11 | -0.28 | -0.15 |
| R&D Expense | 569.35K | 664.88K | 854.62K | 1.14M | 1.15M | 1.37M | 1.86M | 2.57M | 3.24M | 2.39M | 2.37M | 3.15M | 3.64M | 2.96M | 3.19M | 3.71M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 94.09M | 318.72M | 440.52M | 624.29M | 616.56M | 322.20M |
| Operating Income | -14.76M | 15.36M | 21.83M | 15.05M | 28.69M | -178.03M |
| Net Income | -14.80M | 23.74M | 34.58M | 6.86M | 19.99M | -182.40M |
| Diluted EPS | -0.25 | 0.25 | 0.34 | 0.06 | 0.18 | -1.84 |
| R&D Expense | 1.19M | 3.32M | 5.38M | 10.86M | 11.59M | 13.56M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 100.17M | 309.60M | 393.28M | 490.45M | 455.62M | 217.10M |
| Total Equity | 79.36M | 55.00M | 219.58M | 273.23M | 300.79M | 320.92M | 144.01M |
| Cash & Equivalents | - | 32.42M | 175.54M | 157.34M | 59.29M | 89.24M | 51.02M |
| Long Term Debt | - | 142.67K | - | - | 41.59K | 5.21K | 183.84K |
| Total Liabilities | - | 33.23M | 82.55M | 114.35M | 185.28M | 140.44M | 91.23M |
| Current Liabilities | - | 23.50M | 57.88M | 100.16M | 170.12M | 121.81M | 67.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.65M | -1.95M | 28.87M | -64.49M | 70.12M | 34.45M |
| Investing Cash Flow | -6.04M | -8.59M | -38.45M | -29.61M | -10.65M | -39.08M |
| Financing Cash Flow | -812.09K | 155.21M | -6.18M | 1.12M | -24.15M | -50.82M |
| Capital Expenditure | -4.36M | -4.81M | -3.20M | -7.31M | -3.61M | -4.54M |
| Free Cash Flow | -15.02M | -6.76M | 25.67M | -71.81M | 66.50M | 29.91M |
| Share Buybacks | - | 0 | 3.73M | 0 | 13.76M | 10.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -15.7% | 4.8% | 5.0% | 2.4% | 4.7% | -55.3% |
| Net Margin % | -15.7% | 7.4% | 7.9% | 1.1% | 3.2% | -56.6% |
| ROE % | -26.9% | 10.8% | 12.7% | 2.3% | 6.2% | -126.7% |
| ROCE % | -19.2% | 6.1% | 7.4% | 4.7% | 8.6% | -119.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.77% | 3.73M | $1.48M |
| 2 | P.A.W. Capital Corp | 3.54% | 3.50M | $1.39M |
| 3 | Knott David M., Jr. | 2.70% | 2.67M | $1.06M |
| 4 | Peapod Lane Capital LLC | 2.53% | 2.50M | $993.80K |
| 5 | Citadel Advisors Llc | 2.38% | 2.35M | $935.56K |
| 6 | Renaissance Technologies, LLC | 2.28% | 2.25M | $896.11K |
| 7 | S Squared Technology, LLC | 2.08% | 2.06M | $816.97K |
| 8 | Acadian Asset Management. LLC | 1.81% | 1.79M | $712.71K |
| 9 | AQR Capital Management, LLC | 1.73% | 1.71M | $679.31K |
| 10 | Moore Capital Management, LP | 1.48% | 1.47M | $582.34K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DCGO
DCGO | DocGo Inc. Common Stock Financials - Income Statement - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1YU1Q0X00zNFpqQ2Z1V1kzMEtoQ3RCUGJyb2lTVEZHOHEwcm5vdVpxaWdiU3BLRXo4YmhsZTBlbWUxWjJjWUVPcExRQWlNU0NFV1k1NHJZaXFrbVhNckJV?oc=5" target="_blank">DCGO | DocGo Inc. Common Stock Financia…
DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPNnU1czdBSFBqaVAzanliakdxc1dLR05QTXFKMnp1UllVaVlkbzhWMWNQNnNzNUJHaE1NZzFpVEVnYkd2WTRmT3l3ZjJQTnRRNGR2eFFWazQ5RDVxclJ1cjI3NFoxZjl3akpXbTNaN0Z1XzkyY3d0Wi1hZHJVX3VxMDZaWlFXUDY0RUY3dj…
DocGo schedules 5 p.m. webcast to discuss Q2 results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNWmNTZjF4UkE2YjRjbDlGdFdXVktLMUVDUkhJcUpDb29pZS11dElfZGNMbTdEU3Z0YnlmT3BFOS1LeExMTEJBVWFHVVluZ1JaSC01RTM3UEUycUx6dWJLckhqS0FfYmV4cnBXMExPMjVFenlhOWtRYTFqNm1PSnpGZzJuUFFuQ1drMHhaRT…
DCGO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1HQlJEYkNZX011Mmd1WmMyM1Brb19fV2pxUm00ZEZrM1JyTHB5STI4UU9SeF9QMlk5bzN0S1Qxb1k4SlNFYldaWHhYXzhMQzlaMGw0TmRRMHJMX2xOSGVDR0RScElVNnZHTjhjUTlUbEM1SllKYm01YjBB?oc=5" target="_blank">DCG…
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPRmFvVndKRVBEZkFiWjViUHRXOS1vOGw5S2p3b3lzazNqaXdUT1UySnRvOU5xd2drU2ZLaEQyU1JEdFYtTlE0Zm5QZk52dXJLcHZ0dURRamwxZ2ktZnV6dWhhM09Gby1XNFQwa3ZSd3JPcUpUbnFQbmUyQ3JwMzJvSEx1QldfYjRFbF9NaD…
Needham reiterates DocGo stock rating on Hicuity acquisition - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNd0FHa2o4bll3Tkg0ajlPcFBZdEwwYk0yMnF4eE40VmJESVpQVnZKMF9WT0JqcXV1WC1DY2pPSkZ6YVRpUG9maGZXdmJFSUtWZEhJejNSWXV5TElrcWp4YTgwOU82UjhFN3FvQWtDWXdrcG56LTBLSkI4MXFGcl9UbnltZjZmcmN0eGRGVz…
DCGO — Frequently Asked Questions
What is the current share price of DocGo Inc. (DCGO)?
As of 2026-09-07 16:24 PDT, DocGo Inc. (DCGO) trades at $0.40 on NasdaqCM. Its 52-week range is $0.38 to $1.73.
What is the market capitalisation of DCGO?
DocGo Inc. (DCGO) has a market capitalisation of $39.51M on NasdaqCM.
What is the P/E ratio of DCGO?
DCGO trades at a trailing price-to-earnings (P/E) ratio of -0.21. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.47.
What is the return on equity (ROE) of DCGO?
DCGO has a return on equity (ROE) of -97.78%. Its return on capital employed (ROCE) is -119.00%.
Is DCGO a good stock to buy?
This page provides a data-driven analysis of DocGo Inc. (DCGO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.